Original Article



Acupuncture in the Prevention of Chemotherapy-induced Nausea and Vomiting: A Meta-analysis of Randomized Controlled Studies

Xukuo Liu^{1#}, Jianing Zhao^{2#}, Jiao Liu¹, Huanfang Fan², Na Guo², Zhihua Du², Haina Wu² and Dehui Li^{2*}

¹Graduate School of Hebei University of Chinese Medicine, Shijiazhuang, China; ²Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, China

Received: July 07, 2022 | Revised: August 24, 2022 | Accepted: September 13, 2022 | Published: October 24, 2022

Abstract

Background and Aims: Chemotherapy-induced nausea and vomiting (CINV) are both common clinical problems in cancer patients. As a traditional Chinese medicine treatment method, acupuncture has a remarkable healing effect on the treatment of nausea and vomiting, but a systematic meta-analysis is lacking concerning this topic.

Methods: This paper searched the randomized controlled clinical trial literature on acupuncture for the prevention of CINV in the Pubmed, EMBASE, CNKI, WF (WAFANG DATE), Cochrane, and VIP (CQVIP) databases with a search date of October 20, 2021. An independent quality evaluation and effect size extraction of the literature were performed by two researchers, and the meta-analysis and quality evaluation of all the literature was performed using RevMan 5.4. A total of 18 publications meeting the criteria were screened for the meta-analysis with a total of 1,135 patients.

Results: Combined acupuncture prophylaxis was significantly better than other chemotherapy regimens in comparison with conventional chemotherapy regimens (risk ratio (RR) = 1.29; 95% confidence interval (CI): 1.17–1.43, p < 0.00001; odds ratio (OR) = 3.61; 95% CI: 2.19–5.96, p < 0.00001). Combined acupuncture was also effective in the prevention of side effects, such as loss of appetite (RR = 0.64; 95% CI:0.42–0.97, p < 0.00001; OR = 0.52; 95% CI:0.28–0.96, p = 0.04), constipation (RR = 0.57; 95% CI:0.44–0.73, p < 0.00001; OR = 0.30; 95% CI:0.18–0.51, p < 0.00001), and diarrhea (RR = 0.58; 95% CI:0.39–0.86, p < 0.00001; OR = 0.31; 95% CI:0.13–0.72, p < 0.00001).

Conclusions: Acupuncture prevention could reduce the incidence of CINV which has certain research value and thus would be worthy of research trials and clinical application.

#Contributed equally to this work.

Introduction

Chemotherapy is one of the most effective treatments for malignant tumors. Chemotherapy-induced nausea and vomiting (CINV) refers to the symptoms of nausea and vomiting in patients who are diagnosed with malignant tumors after the use of chemotherapy drugs or chemotherapy-related drugs in the period of chemotherapy. However, CINV is the most common adverse reaction during chemotherapy, which occurs with an incidence of over 80%.¹ Moreover, cisplatin causes 100% incidence of nausea and vomiting, which seriously affects the quality of the patients' survival and reduces the patients' adherence.² In severe cases, this could lead to nutritional deficiencies and water-electrolyte imbalance.³ This would make the patients' body resistant to chemotherapy, which would be detrimental to tumor control and the patients' health. Therefore, the effective prevention of CINV would be of great significance to patients with malignant tumors. Although Western

Keywords: Acupuncture; Chemotherapy; Nausea; Vomit; Meta-analysis.

Abbreviations: CI, confidence interval; CINV, chemotherapy-induced nausea and vomiting; Co21, Xuanji acupoint; CV6, Qihai acupoint; CV10, Xiawan acupoint; CV12, Zhongwan acupoint; CV13, Shangwan acupoint; CV17, Danzhong acupoint; HT7, Shenmen acupoint; 5-HT, 5-hydroxytryptamine receptor antagonist; KPS, Karnofsky Performance Scale; LR13, Zhangmen acupoint; OR, odds ratio; PC6, Neiguan acupoint; RCTs, randomized clinical trials; RN4, Guanyuan acupoint; RT3, Zhangmen acupoint; ST25, Tianshu acupoint; ST36, Zusanli acupoint; ST40, Fenglong acupoint.

^{*}Correspondence to: Dehui Li, Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China. ORCID: https://orcid.org/0000-0001-7963-9410. Tel: +86 13230413308, Fax: +86-311-6909526, Email: 258289951@qq.com #Coartilitated envelopment

How to cite this article: Liu X, Zhao J, Liu J, Fan H, Guo N, Du Z, et al. Acupuncture in the Prevention of Chemotherapy-induced Nausea and Vomiting: A Meta-analysis of Randomized Controlled Studies. *Future Integr Med* 2022;1(1):13–22. doi: 10.14218/FIM.2022.00031.

^{© 2022} The Author(s). This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. "This article has been published in *Future Integrative Medicine* at https://doi.org/10.14218/FIM.2022.00031 and can also be viewed on the Journal's website at https://www.xiahepublishing.com/journal/fim".

Future Integr Med

medicine has shown certain advantages in the treatment of CINV, it is less ideal in controlling some specific types of CINV and has certain side effects, such as nausea and vomiting, bone marrow suppression, oral mucosal toxicity, allergic reactions, hair loss, ototoxicity, and nephrotoxicity.

Acupuncture has been used for thousands of years to treat this type of disease and has accumulated a great deal of clinical experience. Furthermore, Chinese medicine contains unique and distinctive insights into CINV, and as a result, holds irreplaceable integral advantages over the treatment of CINV. In addition, the year 1997 witnessed the first announcement by the National Institutes of Health, USA that acupuncture could effectively treat CINV.⁴ In 2002, the World Health Organization (WHO) recommended the use of acupuncture for the treatment of 77 conditions, including adverse effects associated with chemotherapy and radiotherapy.5,6 Then in 2014, the Chinese Guidelines for the Prevention and Treatment of Oncology-Related Vomiting incorporated the combination of Chinese medicine for CINV into the treatment protocol for this condition.7 Following this, in 2016, US experts noted recommendations for increased research into the efficacy management and mechanisms of symptoms associated with acupuncture for malignancy,⁸ as acupuncture had played an increasingly important role in the treatment of CINV. As part of traditional Chinese medicine treatment, acupuncture has the advantage of being simple, inexpensive, and most importantly, effective in the prevention and treatment of nausea and vomiting. As a result, this study collected randomized controlled studies of acupuncture therapy for the prevention of CINV for quality evaluation and a meta-analysis in order to provide an evidence-based basis for the prevention of CINV with acupuncture.

Material and methods

The review is registered with PROSPERO.⁹ The registration number is CRD42021285713.

Inclusion Criteria

- 1. Study design: The original literature was published, and the study method was a randomized controlled trial with no restrictions on the language of the publications.
- Study population: Patients who were diagnosed with a malignant tumor and were undergoing chemotherapy with no nausea and vomiting during this chemotherapy.
- Treatment: The treatment group was treated with acupuncture based on the control group. The control group was receiving a conventional chemotherapy regimen or Western medicine for prophylaxis.
- 4. Outcome assessment: The included literature had clear efficacy evaluation criteria, which set the rates of nausea and vomiting as the primary outcome indicator. In addition to the nausea and vomiting rates, the number of people with diarrhea, the number of people with loss of appetite, and those with a Karnofsky (KPS) score were also identified as outcome indicators.

Exclusion Criteria

- 1. Duplicate publication or duplicate detection of the literature.
- 2. Too few cases were included (less than 10).
- 3. Full text was not available.
- Allergies or combined with serious primary diseases, such as cardiovascular, cerebrovascular, hepatic, renal, and hematopoietic system, patients with diabetes mellitus, psychiatric disorders, and infectious diseases.

Search Strategy

A computerized search of six databases, Pubmed, EMBASE, Cochrane, and CNKI, VIP, WF, was conducted to identify studies that reported randomized clinical trials (RCTs) of acupuncture for tumor-related nausea and vomiting. Chinese search terms included 'acupuncture', 'needling', 'chemotherapy', 'nausea and vomiting', 'and randomised controlled trial'. The English search formula was 'acupuncture'/exp AND 'chemotherapy'/exp AND 'postoperative nausea and vomiting'/exp. Based on the characteristics of the different databases, a comprehensive search was conducted on the characteristics. The literature related to 'randomized control' and 'randomized grouping' was then screened.

Selection of the materials

The results of the literature search were imported into Endnote according to the design protocol. Any duplicates were removed, and all study components were completed independently by two reviewers since they started doing the literature search. Any discrepancies between the two reviewers were resolved by discussing and tracing the original studies according to the above inclusion and exclusion criteria.

Research quality assessment

The quality of the included literature was assessed applying the Cochrane risk of bias tool for studies. The evaluation covered random sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessment, incomplete outcome data and exclusions, selective reporting, and other sources of bias. Each item was categorized as 'high risk', 'low risk', or 'unclear'. Two reviewers conducted the quality checks independently with a third researcher involved in negotiating when disagreements were encountered, and the final risk of the bias assessment map was generated by RevMan 5.4 software.

Data analyses

The meta results were analyzed using RevMan 5.4 software. The reference data for the dichotomous variables were provided in the form of relative risk ratios (RR) and their 95% confidence intervals (CI), and χ^2 tests for heterogeneity between studies. If p > 0.1 I² \leq 50%, this indicated good homogeneity and a fixed-effects model was available. If $p \leq 0.1$; I² > 50%, this showed large heterogeneity; thus, subgroup analysis or sensitivity analysis was required to analyze the source of heterogeneity. If the source of heterogeneity still could not be identified, then a random effect model was selected. A funnel plot analysis was also used to analyze the publication bias.

Results

Inclusion in the study screening process

The initial search identified 520 references. After removing 161 duplicates, 331 references were filtered by examining their titles, abstracts, and keywords. After the first level of screening, 28 full-text articles were read through. Finally, 10 studies were excluded, and the remaining 18 studies were included in the review.^{10–27} In the 18 included studies, the sample sizes involved ranged from 30 to 120 with a total of 563 cases in the treatment group and 572 in the control group, which were all patients with or without post-chemotherapy nausea and vomiting. The process of the search, screening, and selection for the study is shown in Figure 1.

Liu X.K. et al: Acupuncture in the prevention of CINV



Fig. 1. The screening process. WF, WAFANG DATE; VIP, CQVIP.

Basic information for inclusion in the article

The basic information included in the articles is shown in Table 1. 10-27

Documentation characteristics statistics

A total of 18 articles were included comprising two in English^{10,11} and 16 in Chinese^{12–27} of which 10 were published in the past five yea rs,^{11,12,14,17,22–27} six published in 2010–2016,^{10,15,18–21} and one article published before 2010.¹³ A total of 48 acupoints were selected from the 18 articles, of which the most frequently used was the Zusanli acupoint (ST36) with 563 times of adoption, accounting for 82.11% of the total, followed by the Neiguan acupoint (PC6) with 504 times, accounting for 44.40% of the total, and the third was the Zhongwan acupoint (CV12) with 270 times, accounting for 23.78% of the total, respectively. The remaining acupoints were used no more than 10 times. Of the tumors studied in the article, two were breast cancer, three were lung cancer, one was a lymphoma, one was a multiple myeloma patient, and 11 were multiple malignancy patients.

Risk of bias

Of the random sequence generation, seven mentioned random number tables; three mentioned random envelopes, four mentioned random controls, and four mentioned randomizations. Of the allocation concealments, one mentioned the complete concealment method and the rest did not. Of those blinded to the investigators and implementers, six were noted to be single-blind and the remainder were not. Of the completeness of the outcome data, six articles noted shedding, and the remainder did not. The Cochrane risk of bias assessment for the included articles is presented in Figure 2. The results showed a high risk of bias in four trials, a moderate risk of bias in 13 trials, and a low risk of bias in one trial. The high risk of bias was due to the lack of blinding to the participants, personnel, and outcome assessors, no mention of allocation concealment, and lack of rigor in the random sequence generation.

The lack of blinding to the outcome assessors and no mention of allocation concealment resulted in a medium risk, and the lack of blinding for the outcome assessors resulted in a low risk (Fig. 2).

Meta-analysis results

Total effective rate

Seven studies reported the effectiveness of CINV after acupuncture.^{10,12–14,16,19,25} Of the 234 cases in the treatment group, 200 were effective, whereas of the 234 cases in the control group, 177 were effective (See Supplementary Table 1). The meta-analysis of the heterogeneity tests showed $\chi^2 = 6.56$, p = 0.36, and $I^2 = 9\%$ with no significant differences between the studies, thus allowing for a fixed-effects model. The effective rate of treating nausea and vomiting was higher in the treatment group than in the control group, which had a statistically significant difference (n = 468, RR = 1.29; 95% CI:1.17–1.43, p < 0.00001; OR = 3.61; 95%CI:2.19– 5.96, p < 0.00001; Fig. 3a).

Nausea rates

Eleven studies reported the number of nausea cases after acupuncture.^{11–13,15,17,20–22,24–26} Of the 353 cases in the treatment group, 283 were nausea-free, whereas of the 354 cases in the control group, 213 were nausea-free (See Supplementary Table 1). The heterogeneity tests in the meta-analysis showed $\chi^2 = 12.07$, p = 0.28, and $I^2 = 17\%$ with no significant differences between the studies, thus allowing for a fixed-effects model. The rate of nausea-free was higher in the treatment group than in the control group, and the difference was statistically significant (n = 707, RR = 1.33; 95% CI:1.20–1.46, p< 0.00001; OR = 2.84; 95% CI:1.99–4.04, p < 0.00001; Fig. 3b).

Vomiting rates

Ten studies reported the number of vomiting cases after acupunc-

Table 1. Basic information about the article

Study authors and year	Tumor type	т	С	Chemotherapy regimens	Acupuncture points	Intervention
Ling-Ling Wang 2020 ¹⁷	Breast cancer	31	30	EC-T program	PC6, CV12, ST36, ST21, and matching time and space acupoints	Acupuncture + (5-HT)5- hydroxytryptamine receptor antagonist
Jing Xuan 2020 ²⁵	Non-small cell lung cancer	30	30	GP program	Stomachache acupoint, PC6	Acupuncture + 5-HT
Tai Liu 2020 ²²	Multiple malignant tumors	33	33	Regular program	ST36, PC6, CV17, Co21	Acupuncture + 5-HT
Qi Guo 2020 ²⁶	Multiple malignant tumors	32	32	Regular program	ST36, PC6, CV12, SP4, ST25, CV6, RN4	Acupuncture + 5-HT
Meng-Jun Dan 2020 ¹²	Adenocarcinoma of the lung	37	36	AP DP TP program	Heart 1, 2, and 3 acupoints and the upper and lower Mars acupoints	Acupuncture + 5-HT
Yun Yang 2019 ²⁷	Multiple malignant tumors	28	30	Cisplatin program	ST36	Acupuncture + 5-HT
Rui Gao 2019 ¹⁴	Lymphoma	41	41	Regular program	CV1, Shuifen Acupoint, RN4, CV6, ST25, Daheng Acupoint, ST36	Acupuncture + 5-HT
Lei Chen 2017 ²⁴	Multiple myeloma	21	23	Regular program	ST36, CV12, PC6, ST40	Acupuncture + 5-HT
Yin Xu 2016 ¹⁶	Multiple malignant tumors	22	22	Cisplatin program	CV12, CV13, CV10, CV6, ST25, ST36, PC6, Baihui Acupoint, shenting Acupoint, yintang Acupoint	Acupuncture + 5-HT
Wei-Qi Li2016 ²⁰	Lung, breast, or gynecological cancers	27	30	Regular program	ST36, PC6, CV12, LR13, ST25, CV6	Acupuncture + 5-HT
Ji-Bin Chen 2016 ¹⁹	Lung Cancer	29	30	EP program	ST36, ST25, CV12, PC6	Acupuncture + 5-HT
Jin-Sheng Lv 2012 ¹⁸	Multiple malignant tumors	25	30	Cisplatin program	ST36, PC6, CV12	Acupuncture + 5-HT
Ye-Ke Li 2012 ²¹	Breast cancer	32	32	ACT program	ST36	Acupuncture + 5-HT
Li Ding 2011 ¹⁵	Multiple malignant tumors	13	15	Cisplatin program	CV13, CV12, CV10, CV6, ST25, ST36, PC6	Acupuncture + 5-HT
Kulthida Rith2015 ¹⁰	Gynecological cancer	35	35	Paclitaxel and carboplatin program	PC6	Acupuncture + 5-HT
Qi-Wei Li2020 ¹¹	Lung, breast or gynecological cancers	62	58	Cisplatin, anthracycline, or paclitaxel regimens	ST36, PC6, CV12, LR13, CV6, ST25	Acupuncture + 5-HT
Qiang Fu 2003 ¹³	Leukemia, lymphoma, myeloma	40	40	DA, HOAP, VDLP, CHOP program	ST36, PC6	Acupuncture + 5-HT
Jing-Ting Xu 2020 ²³	Multiple malignant tumors	25	25	Cisplatin program	ST36, PC6, SP4, SP3, HT7	Acupuncture + 5-HT

Co21, Xuanji acupoint; CV6, Qihai acupoint; CV10, Xiawan acupoint; CV12, Zhongwan acupoint; CV13, Shangwan acupoint; CV17, Danzhong acupoint; HT7, Shenmen acupoint. KPS, Karnofsky Performance Scale; LR13, Zhangmen acupoint; PC6, Neiguan acupoint; RN4, Guanyuan acupoint; SP4, Gongsun acupoint; ST21, Liangmen acupoint; ST25, Tianshu acupoint; ST36, Zusanli acupoint; ST40, Fenglong acupoint.

ture.^{11,13,15,17,20,22,24–27} Of the 312 cases in the treatment group, 271 were vomit-free, whereas of the 314 cases in the control group, 208 were vomit-free (See Supplementary Table 1). The heterogeneity tests in the meta-analysis showed $\chi^2 = 15.41$, p = 0.08, and $I^2 = 42\%$ with no significant differences between the studies, hence allowing for a fixed-effects model. The vomiting-free rate was higher in the

treatment group than in the control group, and the difference was statistically significant (n = 626, RR = 1.30;95% CI:1.20–1.42, p < 0.00001; OR = 4.06; 95% CI:2.59–6.35, p < 0.00001; Fig. 3c).

Diarrhea

Three studies reported the number of diarrhea cases after acupunc-



Fig. 2. Risk of the bias analysis. Red (High risk), yellow (Standard risk), green (Low risk).

ture.^{16,21,23} Of the 79 cases in the treatment group, 19 had diarrhea, whereas of the 79 cases in the control group, 33 had diarrhea (See Supplementary Table 1). The heterogeneity test in the meta-analysis showed $\chi^2 = 0.56$, p = 0.76, and $I^2 = 0\%$ with no significant differences between the studies, thus allowing for a fixed-effects

model. The number of diarrhea cases in the treatment group was lower than in the control group, and the difference was statistically significant (n = 168, RR = 0.58; 95% CI:0.39–0.86, p < 0.00001; OR = 0.31; 95% CI:0.13–0.72, p < 0.00001; Fig. 4a).

Constipation

Six studies reported the number of people constipated after acupuncture.^{10,13,16,18,21,24} Of the 180 cases in the treatment group, 47 had constipation, whereas of the 182 cases in the control group, 85 had constipation (See Supplementary Table 1). The heterogeneity tests in the meta-analysis showed $\chi^2 = 4.71$, p = 0.45, and $I^2 = 0\%$ with no significant differences between the studies, thus allowing for a fixed-effects model. The number of constipation cases was lower in the treatment group than in the control group, and the difference was statistically significant (n = 362, RR = 0.57;95% CI:0.44–0.73, p < 0.00001; OR = 0.30; 95% CI:0.18–0.51, p <0.00001; Fig. 4b).

Appetite loss

Five studies reported on the number of cases of loss of appetite after acupuncture. ^{10,16,18,21,24} Of the 140 cases in the treatment group, 24 experienced loss of appetite, whereas of the 142 cases in the control group, 39 experienced loss of appetite (See Supplementary Table 1). The heterogeneity test in the meta-analysis showed $\chi^2 = 1.63$, p = 0.80, and $I^2 = 0\%$ with no significant differences between the studies, thus allowing for a fixed-effects model. The number of cases of loss of appetite was lower in the treatment group than in the control group, and the difference was statistically significant (n = 282, RR = 0.64; 95% CI:0.42–0.97, p < 0.00001; OR = 0.52; 95% CI:0.28–0.96, p = 0.04; Fig. 4c).

Karnofsky performance scale (KPS) score

Six studies reported on post-needling Karnofsky Performance Scale (KPS) scores.^{17–19,22,23,26} Overall, there were 180 cases in the treatment group and 180 in the control group. The meta-analysis of the heterogeneity tests showed that the differences between the studies were statistically significant with $\chi^2 = 24.89$, p = 0.00001, and I² = 80%, hence allowing for a random-effects model. The difference was statistically significant in the treatment group with a lower KPS score than the control group (n = 360, standardized mean difference = 7.12, 95% CI:3.35–10.88, Z = 3.71, p = 0.0002; Fig. 4d).

Subgroup analysis

Chemotherapy regimen subgroup analysis: A meta-analysis of seven studies of the chemotherapeutic drug subgroups comprised 234 cases in the trial group and 234 cases in the control group.^{10,12–14,16,19,25} The test of heterogeneity (p = 0.75; $I^2 = 0\%$) indicated that there was no significant difference between the groups, and a fixed-effects model was used for the meta-analysis. The subgroup analysis was performed by different chemotherapy regimens. The groups were classified as the acupuncture group with cisplatin chemotherapy regimen, and the acupuncture group with conventional chemotherapy regimen (Fig. 5). In the cisplatin chemotherapy regimen group, the conventional chemotherapy regimen group showed a better antiemetic effect in the treatment group than in the control group. The conventional chemotherapy regimen group (p = 0.0009) and the cisplatin regimen group (p = 0.0001) resulted in p < 0.05 for the two groups, and the difference was statistically significant. The specific results are shown in Figure 5.

Cancer subgroup analysis: A meta-analysis of seven studies of the chemotherapeutic drug subgroups consisted of 234 cases in the

Future Integr Med

Liu X.K. et al: Acupuncture in the prevention of CINV

	ר
C	7

•	Experim	ental	Control			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ji-Bin Chen2016	28	29	25	30	15.9%	1.16 [0.97, 1.38]	
Jing Xuan2020	25	30	18	30	11.6%	1.39 [1.00, 1.94]	
Kulthida Rithirangsriroj 2015	18	35	12	35	7.7%	1.50 [0.86, 2.63]	
Meng-Jun Dan2020	32	37	24	36	15.7%	1.30 [1.00, 1.69]	
Qiang Fu2003	38	40	34	40	21.9%	1.12 [0.96, 1.30]	+
Rui Gao2019	38	41	26	41	16.8%	1.46 [1.14, 1.87]	_
Yin Xu2016	21	22	16	22	10.3%	1.31 [1.00, 1.72]	
Total (95% CI)		234		234	100.0%	1.29 [1.17, 1.43]	•
Total events	200		155				
Heterogeneity: Chi ² = 6.56, df =	= 6 (P = 0.3	36); l² =	9%				
Test for overall effect: Z = 5.04	(P < 0.000	Favours [experimental] Favours [control]					

	Experime	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Jing-Ting Xu2020	17	25	7	25	3.3%	2.43 [1.23, 4.81]	· · · · ·
Lei Chen2017	12	21	6	23	2.7%	2.19 [1.00, 4.78]	
Li Ding2011	9	13	7	15	3.0%	1.48 [0.77, 2.85]	
Ling-Ling Wang2020	31	31	20	30	9.7%	1.49 [1.15, 1.92]	
Meng-Jun Dan2020	29	37	20	36	9.5%	1.41 [1.01, 1.98]	
Qiang Fu2003	34	40	30	40	14.0%	1.13 [0.91, 1.41]	+
Qi Guo2020	27	32	19	32	8.9%	1.42 [1.03, 1.96]	
Qi-Wei Li2016	20	27	22	30	9.7%	1.01 [0.74, 1.38]	
Qi-Wei Li2020	52	62	39	58	18.8%	1.25 [1.01, 1.54]	
Tai Liu2020	20	33	17	33	7.9%	1.18 [0.77, 1.81]	
Ye-Ke Li2012	32	32	26	32	12.4%	1.23 [1.03, 1.46]	
Total (95% CI)		353		354	100.0%	1.33 [1.20, 1.46]	•
Total events	283		213				
Heterogeneity: Chi ² = 1	2.07, df = 7	10 (P =	0.28); l ² =	17%			<u> </u>

1	
	ر

	Experimental		Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Jing-Ting Xu2020	18	25	12	25	5.8%	1.50 [0.93, 2.41]	
Lei Chen2017	10	21	3	23	1.4%	3.65 [1.16, 11.49]	
Li Ding2011	12	13	7	13	3.4%	1.71 [1.01, 2.90]	
Ling-Ling Wang2020	31	31	25	30	12.4%	1.20 [1.01, 1.42]	
Qiang Fu2003	38	40	31	40	14.9%	1.23 [1.02, 1.47]	
Qi Guo2020	30	32	19	32	9.1%	1.58 [1.17, 2.13]	
Qi-Wei Li2016	25	27	25	30	11.4%	1.11 [0.92, 1.35]	
Qi-Wei Li2020	57	62	48	58	23.8%	1.11 [0.97, 1.28]	
Tai Liu2020	25	33	18	33	8.6%	1.39 [0.96, 2.00]	
Yun Yang2019	25	28	20	30	9.3%	1.34 [1.01, 1.78]	
Total (95% CI)		312		314	100.0%	1.30 [1.20, 1.42]	•
Total events	271		208				
Heterogeneity: Chi ² = 1	15.41, df =	9 (P = 0	.08); l ² = 4	42%			
Test for overall effect: 2	Z = 6.18 (P	< 0.000	01)				0.2 0.5 1 2 5 Favours [experimental] Favours [control]

Fig. 3. Meta-analysis of the clinical efficiency, nausea rate, and vomiting rate. (a) Clinical efficiency meta-analysis; (b) nausea rate meta-analysis; (c) vomit rate meta-analysis. CI, confidence interval.

test group and 234 cases in the control group.^{10,12–14,16,19,25} The test of heterogeneity (p = 0.54; $I^2 = 0\%$) showed that there was no significant difference between the groups. and a fixed-effects model was used for the meta-analysis. The subgroup analysis was performed by different chemotherapy regimens. They were divided into the multiple malignancies group, lung cancer group, and lymphoma cancer group (Fig. 6). The multiple malignancies,

lung cancer, and lymphoma cancer showed that the antiemetic effect of the treatment group was better than that of the control group. The antiemetic effect in the multiple malignancies group (p = 0.0008), lung cancer group (p = 0.001), and lymphoma group (p = 0.003) resulted in p < 0.05 for the three groups, and the difference was statistically significant. The specific results are shown in Figure 6.

Liu X.K. et al: Acupuncture in the prevention of CINV



b

•	Experim	ental	Control			Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fix	ed, 95% Cl		
Jin-Sheng Lv2012	5	30	9	30	10.6%	0.56 [0.21, 1.46]			+		
Kulthida Rithirangsriroj 2015	19	35	31	35	36.6%	0.61 [0.44, 0.85]					
Lei Chen2017	12	21	16	23	18.0%	0.82 [0.52, 1.30]			+		
Qiang Fu2003	0	40	4	40	5.3%	0.11 [0.01, 2.00]	•		+		
Ye-Ke Li2012	8	32	17	32	20.1%	0.47 [0.24, 0.93]		•			
Yin Xu2016	3	22	8	22	9.4%	0.38 [0.11, 1.23]	← •		+-		
Total (95% CI)		180		182	100.0%	0.57 [0.44, 0.73]		\bullet			
Total events	47		85								
Heterogeneity: Chi ² = 4.71, df =	L		+								
Test for overall effect: Z = 4.39	(P < 0.000	0.∠ Favour	0.5 [experimental]	Favours [co	ntrol]						

С

		Experim	ental	Contr	ol		Risk Ratio		Ris	k Ratio	
_	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fiz	ced, 95% Cl	
	Jin-Sheng Lv2012	6	30	8	30	20.9%	0.75 [0.30, 1.90]				
	Kulthida Rithirangsriroj 2015	2	35	7	35	18.3%	0.29 [0.06, 1.28]	← ■		+	
	Lei Chen2017	9	21	15	23	37.4%	0.66 [0.37, 1.17]			+-	
	Ye-Ke Li2012	6	32	7	32	18.3%	0.86 [0.32, 2.27]	_	•	+	
	Yin Xu2016	1	22	2	22	5.2%	0.50 [0.05, 5.12]	•			
	Total (95% CI)		140		142	100.0%	0.64 [0.42, 0.97]			-	
	Total events	24		39							
	Heterogeneity: Chi ² = 1.63, df	= 4 (P = 0.8	80); l² =	0%							
	Test for overall effect: Z = 2.08	8 (P = 0.04))					0.2 Favou	u.o rs [experimental]	Favours [control]	5

d

J	Exp	erimenta	al	c	Control		Mean Difference			Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Rai	<u>ıdom, 95%</u>	6 CI	
Ji-Bin Chen2016	27.931	12.056	29	18.333	14.341	30	12.8%	9.60 [2.85, 16.35]				_	
Jing-Ting Xu2020	85.2	8.23	25	80.6	8.93	25	16.2%	4.60 [-0.16, 9.36]					
Jin-Sheng Lv2012	75.43	0.48	30	68.67	9.54	30	18.5%	6.76 [3.34, 10.18]					
Ling-Ling Wang2020	96.77	4.75	31	84.33	5.04	30	20.0%	12.44 [9.98, 14.90]			-	-	
Qi Guo2020	78.65	9.84	32	70.88	11.48	32	15.4%	7.77 [2.53, 13.01]				-	
Tai Liu2020	60	9.35	33	58.79	8.2	33	17.1%	1.21 [-3.03, 5.45]			-		
Total (95% CI)			180			180	100.0%	7.12 [3.35, 10.88]			•		
Heterogeneity: Tau ² = Test for overall effect:	16.84; Ch Z = 3.71 ($pi^2 = 24.8$ P = 0.00	9, df = 02)	5 (P = 0.0	0001); I²	= 80%			⊢ -50 Fa	-25 vours [experimenta	0 al] Favou	25 rs [control]	50

Fig. 4. Meta-analysis of diarrhea, constipation, appetite loss, and KPS. (a) meta-analysis of the number of people with diarrhea; (b) meta-analysis of the number of people with appetite loss; (d) meta-analysis of the number of people with a KPS score. CI, confidence interval; KPS, Karnofsky Performance Scale.

Analysis of publication bias

Eleven publications included in the study were analyzed by applying RevMan 5.4 software.^{11–13,15,17,20–22,24–26} From the funnel plot analysis, it could be seen that the publications were concentrated, not located on either side of the funnel plot, and not symmetrically distributed. This suggested the existence of some publication bias, which could be related to the low quality of the included studies. The results are shown in Figure 7.

Discussion

The traditional Chinese medicine name for CINV corresponds to "vomiting", and the basic pathogenesis is the loss of harmony and of the stomach and the upward rebellion of gastric energy. Therefore,

Future Integr Med

Liu X.K. et al: Acupuncture in the prevention of CINV

	Experim	ental	Control		Risk Ratio		Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl					
3.2.1 cisplatin regimen group)											
Ji-Bin Chen2016	28	29	25	30	15.9%	1.16 [0.97, 1.38]	-					
Jing Xuan2020	25	30	18	30	11.6%	1.39 [1.00, 1.94]						
Kulthida Rithirangsriroj 2015	18	35	12	35	7.7%	1.50 [0.86, 2.63]	+					
Meng-Jun Dan2020	32	37	24	36	15.7%	1.30 [1.00, 1.69]						
Yin Xu2016	21	22	16	22	10.3%	1.31 [1.00, 1.72]						
Subtotal (95% CI)		153		153	61.3%	1.31 [1.14, 1.50]	•					
Total events	124		95									
Heterogeneity: Chi ² = 2.20, df = 4 (P = 0.70); l ² = 0%												
Test for overall effect: Z = 3.86	(P = 0.000)	01)										
3.2.2 conventional chemothe	rapy regir	nen gro	oup									
Qiang Fu2003	38	40	34	40	21.9%	1.12 [0.96, 1.30]						
Rui Gao2019	38	41	26	41	16.8%	1.46 [1.14, 1.87]						
Subtotal (95% CI)		81		81	38.7%	1.27 [1.10, 1.46]	•					
Total events	76		60									
Heterogeneity: Chi ² = 4.02, df =	= 1 (P = 0.0	05); l² =	75%									
Test for overall effect: Z = 3.31	(P = 0.000)9)										
		,										
Total (95% CI)		234		234	100.0%	1.29 [1.17, 1.43]	•					
Total events	200		155									
Heterogeneity: Chi ² = 6.56, df =	= 6 (P = 0.3	36); l² =	9%									
Test for overall effect: Z = 5.04	(P < 0.000	001)					0.01 0.1 1 10 100					
Test for subaroup differences:	Chi ² = 0.10). df = 1	(P = 0.75). I ² = ()%		Favours [experimental] Favours [control]					

Fig. 5. Subgroup analysis of the chemotherapy regimens. CI, confidence interval.

the principle of the treatment is to regulate the elevation of the spleen and stomach, harmonize the stomach, and subdue the rebellion to stop vomiting. In the treatment of nausea and vomiting, the stomach meridian, pericardium meridian, and Ren meridian are the preferred meridians, and ST36, PC6, and CV12 are the commonly used acupoints.²⁸ This is also the lower acupoint of the stomach, which has the

	Experime	ental	Contr	ol		Risk Ratio	Risk Ratio					
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl					
3.1.1 multiple malignancies	group											
Kulthida Rithirangsriroj 2015	18	35	12	35	7.7%	1.50 [0.86, 2.63]	+					
Qiang Fu2003	38	40	34	40	21.9%	1.12 [0.96, 1.30]	-					
Yin Xu2016	21	22	16	22	10.3%	1.31 [1.00, 1.72]	-					
Subtotal (95% CI)		97		97	40.0%	1.24 [1.06, 1.46]	•					
Total events	77		62									
Heterogeneity: Chi ² = 2.54, df = 2 (P = 0.28); l ² = 21%												
Test for overall effect: Z = 2.67	' (P = 0.008	5)										
3.1.2 lung concor group												
li Pin Chon2016	20	20	25	20	15 0%	1 16 [0 07 1 29]	-					
Jing Yuan2020	20	29	10	20	11.8%	1.10 [0.97, 1.30]						
	20	30	24	30	15.7%	1.39 [1.00, 1.94]						
Subtotal (95% CI)	52	96	24	96	43.2%	1 27 [1 10 1 47]	♦					
Total events	85	00	67		-10.2 /0	1.27 [1.10, 1.47]	ľ					
Heterogeneity: $Chi^2 = 1.38$ df	= 2 (P = 0 5	$50) \cdot 1^2 =$	0%									
Test for overall effect: $Z = 3.18$	P = 0.001)	070									
		,										
3.1.4 lymphoma group												
Rui Gao2019	38	41	26	41	16.8%	1.46 [1.14, 1.87]	+					
Subtotal (95% CI)		41		41	16.8%	1.46 [1.14, 1.87]	◆					
Total events	38		26									
Heterogeneity: Not applicable												
Test for overall effect: Z = 3.00) (P = 0.003	5)										
Total (95% CI)		234		234	100.0%	1.29 [1.17, 1.43]	•					
Total events	200		155									
Heterogeneity: Chi ² = 6.56, df	= 6 (P = 0.3	86); I² =	9%									
Test for overall effect: Z = 5.04	+ (P < 0.000	01)					Favours [experimental] Favours [control]					
Test for subaroup differences:	Chi ² = 1.23	. df = 2	(P = 0.54)). $ ^2 = ($)%							

Fig. 6. Subgroup analysis of cancer. CI, confidence interval.

Liu X.K. et al: Acupuncture in the prevention of CINV



Fig. 7. Publication bias analysis. RR, risk ratio.

function of regulating internal Qi, lowering rebelliousness and stopping vomiting, and tonifying stomach Qi; PC6 is a ligament acupoint of the Hand Convulsive Yin Pericardium meridian, which is connected to the Hand Shaoyang Sanjiao meridian, and can communicate with both the surface and the interior meridians, unblocking the Sanjiao Qi, and is responsible for broadening the chest and regulating Qi, lowering rebelliousness and stopping vomiting.²⁹ In addition, it is one of the eight rendezvous acupoints with the "Gong Sun Chong pulse of the stomach and heart and chest". CV12, belonging to the Ren Vessel, is a meeting of the Ren Vessel, the Hand Sun and Shao Yang, and the Foot Yang Ming. It is a recruitment acupoint for the stomach and the meeting of the internal organs of the eight Hui acupoints. It has the effect of harmonizing the stomach and strengthening the spleen, lowering the rebellion, and inducing diuresis. Modern research has found that ST36 can regulate the function of the intestinal tract movement.³⁰ It also has the effect of increasing the serum levels of gastrin and decreasing the levels of vasoactive peptides.³¹ PC6 can prevent nausea and vomiting by the mechanism of reducing the 5-hydroxytryptamine concentrations in the plasma and intestinal tissues.³² Modern research has also found that acupuncture at CV12 enhances gastrointestinal peristalsis, promotes the secretion of digestive juices, and accelerates gastrointestinal blood circulation.³³ In summary, all three acupoints can treat tumor-related nausea and vomiting.

Limitations of this study: 1) It was difficult to conduct doubleor triple blinding considering the specificity of the acupuncture therapy. 2) It was difficult to form standardized treatment due to the different degrees of mastery of the acupuncture theory and different acupuncture acupoints by the acupuncture practitioners. 3) The evaluation of the efficiency of nausea and vomiting was subjective and lacked objective evaluation. 4) Some of the literature included small samples. 5) Most of the adverse effects and followup results were not reported.

Future directions

In the future, we will conduct research on acupuncture in the treatment of CINV, further refine the inclusion and exclusion criteria, and include sufficient large samples and multicenter randomized controlled trials, so that the outcome indicators would be more objective and comprehensive, and more acupoints would be mined.

Conclusions

Based on the available literature, it could be tentatively concluded

Future Integr Med

that acupuncture prevention could reduce the incidence of CINV, which had some value and some improvement in other concomitant symptoms of chemotherapy and gastrointestinal reactions. Furthermore, acupuncture could better improve the CINV patients' karst score and improve their quality of life; thus, it would be worth in research experiments and clinical promotion. The main acupoints for the treatment of CINV were ST36, PC6, and CV12.

Outlook: Given the limitations of these studies, future RCTs studies should confirm the efficacy and safety of acupuncture for CINV. The following aspects would therefore need to be taken into account when designing clinical RCTs: 1. conducting high-quality, large-sample, multicenter randomized controlled trials with objective outcome indicators, uniform and consistent assessment criteria, and standardized protocol design; 2. blinding the data statisticians and report analysts; 3. documenting the follow-up and reporting the adverse effects; 4. conducting studies based on the Consolidated Standards of Reporting Trials and the Standards for Reporting Trials and Standards for Reporting in Clinical Trials of Interventions Acupuncture; 5. report on the details of the acupuncture, such as the depth of the insertion of the needle, the technique used to insert the needle, how long the needle lasts, duration of the acupuncture sessions, the qualifications of the acupuncturist, and years of clinical practice.

Supporting information

Supplementary material for this article is available at https://doi.org/10.14218/FIM.2022.00031.

Supplementary Table 1. CINV related data table.

Acknowledgments

None.

Funding

This research was supported by the National Natural Science Foundation of China (Grant no. 81603412); Hebei Province "Three Three Three Talent Project" funded project (Grant no. A202002008). General Projects for Improving Scientific Research Capacity of Hebei College of Traditional Chinese Medicine (Grant no. KTY2019009); Key Laboratory of Integrated Traditional Chinese and Western Medicine Hepatonephrosis in Hebei Province (Grant no. A201902), 2022 Medical science research project of Hebei Province (20220962).

Conflict of interest

DHL has been an editorial board member of *Future Integrative Medicine* since November 2021. The other authors report no conflict of interests in this work.

Author contributions

DHL, JNZ, and HFF designed the research, prepared the data, wrote and revised the manuscript; XKL, JL, NG, ZHD, and HNW collected the data and translated the manuscript. The final manuscript was read and approved by all authors.

Data sharing statement

The data used to support the findings of this study are available

from the corresponding author upon request.

References

- Wei Y. Application of antiemetic instrument combined with traditional Chinese medicine nursing in the treatment of chemotherapy nausea and vomiting. World Latest Medicine Information 2018;18(65):232. doi:10.19613/j.cnki.1671-3141.2018.65.177.
- [2] McDonagh M, Peterson K, Thakurta S. Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults. Available from: https://www. hhs.gov/guidance/document/consideration-evidence-antiemeticdrugs-nausea-and-vomiting-associated-chemotherapy-or-0. Accessed September 19, 2022.
- [3] Jiang WQ, Ba Y, Feng JF. Chinese experts' consensus on the prevention and treatment of nausea and vomiting related to anti-cancer drug treatment (2019 version). Chinese Journal of the Frontiers of Medical Science 2019;11(11):16–26. doi:10.12037/YXQY.2019.11-04.
- [4] Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. Alternative Methods to Treat Nausea and Vomiting from Cancer Chemotherapy. Chemother Res Pract 2015;2015:818759. doi:10.1155/2015/818759, PMID:26634155.
- [5] Word Health Organizaton. Acupuncture-Review and Analysis of Reports on Controlled Clinical Tial. Geneva: World Health Organizaton; 2002.
- [6] An Q, Liu PD, Liu YY, Zhao TY. Responsibility of Acupuncture in Tumor Therapy: Literature Review of High- quality Research on Acupuncture and Moxibustion Intervention in Tumor in Recent 5 Years. World Chinese Medicine 2021;16(8):9. doi:10.3969/j.issn.1673-7202.2021.08.027.
- [7] Wang S, Geng L. Clinical Study on TCM Acupuncture Treatment of Chemotherapy-Induced Nausea and Vomiting Patients with Different Syndromes. Acta Chinese Medicine 2017;32(10):4. doi:10.16368/j. issn.1674-8999.2017.10.487.
- [8] Zia FZ, Olaku O, Bao T, Berger A, Deng G, Fan AY, et al. The National Cancer Institute's Conference on Acupuncture for Symptom Management in Oncology: State of the Science, Evidence, and Research Gaps. J Natl Cancer Inst Monogr 2017(52):lgx005. doi:10.1093/jncimonographs/lgx005, PMID:29140486.
- [9] Vrabel M. Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Oncol Nurs Forum 2015;42(5):552–554. doi:10.1188/15. ONF.552-554, PMID:26302284.
- [10] Rithirangsriroj K, Manchana T, Akkayagorn L. Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol 2015;136(1):82– 86. doi:10.1016/j.ygyno.2014.10.025, PMID:25449310.
- [11] Li QW, Yu MW, Wang XM, Yang GW, Wang H, Zhang CX, et al. Efficacy of acupuncture in the prevention and treatment of chemotherapyinduced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research. Chin Med 2020;15:57. doi:10.1186/s13020-020-00333-x, PMID:32514290.
- [12] Dan MJ, Guo HR, Yin JH, Shen LP, Xin XL, Jiang Y, et al. Clinical Observation on Dong's Extra Acupoint Acupuncture in Preventing Treating Nausea and Vomiting Caused by Chemotherapy for Advanced Lung Adenocarcinoma. Journal of Oncology in Chinese Medicine 2020;2(5):20–23. doi:10.19811/j.cnki.ISSN2096-6628.2020.05.005.
- [13] Fu Q, Xiong YJ, Li NL. Clinical observation on ondansetron combined with acupuncture preventing and treating nausea and vomiting Induced by chemotherapy. Clinical Medicine of China 2003;19(3):2. doi:10.3760/cma.j.issn.1008-6315.2003.03.032.
- [14] Gao R, Pei SL, Meng ZY. Influence of abdominal acupuncture combined with acupuncture at Zusanli on gastrointestinal side effects of lymphoma patients after chemotherapy. Chinese Journal of Convalescent Medicine 2019;28(8):3. doi:10.13517/j.cnki.ccm.2019.08.030.
- [15] Ding L. Clinical Observation on the Prevention and Treatment of Gastrointestinal Symptoms Caused by Chemotherapy Drug (Cisplatin) with Lao Shi Needle. Beijing: Beijing University of Chinese Medicine; 2011.

Liu X.K. et al: Acupuncture in the prevention of CINV

- [16] Xu Y, Cheng YB, Liu LN. Clinical Observation of Prevention for gastrointestinal symptoms caused by Chemotherapy (Cisplatin) with old ten-needles. Chinese Archives of Traditional Chinese Medicine 2016;34(2):359–361.
- [17] Wang LL. Clinical Study on Nausea and Vomiting caused by postoperative Chemotherapyin Breast cancer with Space-time Acupuncture program of Ling Turtle Eight Methods. Kunming: Yunnan University of Chinese Medicine; 2020.
- [18] Lv JS. The Clinical observation of "Stomach three needle" preventing and controlling Nausea and Vomit by Chemotherapy. Guangzhou: Guangzhou University of Chinese Medicine; 2012.
- [19] Chen JB. The effect for nausea and vomiting of acupuncture to patients with lung cancer after the first-time chemotherapy. Guangzhou: Guangzhou University of Chinese Medicine; 2016.
- [20] Li QW. Clinical study on acupuncture in preventing and treating nausea and vomiting after chemotherapy for malignant tumor. Beijing: Beijing University of Chinese Medicine; 2016.
- [21] Li YK. Clinical Study on Effect of Acupuncture in prevention and treatment of Nausea and Vomiting induced by Breast Cancer Chemotherapy. Guangzhou: Guangzhou University of Chinese Medicine; 2012.
- [22] Liu T. The clinical study of Chemotherapy-induced nausea and vomiting adopting "Jiangni group acupoints". Beijing: China academy of Chinese Medical Sciences; 2020.
- [23] Xu JT. Clinical observation of acupuncture combined with ondansetron in the treatment of chemotherapy-induced nausea and vomiting. Beijing: Beijing University of Chinese Medicine; 2020.
- [24] Chen L, Li Q, Liu WG. Efficacy observation of acupuncture therapy in alleviating adverse reactions after chemotherapy in patients with multiple myeloma. Proceedings of the 2nd Annual Academic Meeting of Acupuncture and Rehabilitation Branch of China Association for the Promotion of Traditional Chinese Medicine and the 9th Annual Academic Meeting of Shandong Acupuncture Society; 2017 Aug; Jinan, Shangdong; 2017.
- [25] Xuan J, Ding QG, Xuan F. Clinical study of acupuncture at Weitong and Neiguan points in the treatment of 30 patients with nausea and vomiting caused by chemotherapy in NSCLC. World Latest Medicine Information 2020;20(73):199–200. doi:10.3969/j.issn.1671-3141.2020.73.116.
- [26] Guo Q. Randomized Controlled Study on Acupuncture Pretreatment for Chemotherapy-related Nausea and Vomiting. Urumchi: Xinjiang medical university; 2020.
- [27] Yang Y, Zhang SQ, Li Y. Acupuncture and moxibustion in the treatment of delayed vomiting after chemotherapy and its effect on the content of substance P. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine. 2019;19(08):50–52.
- [28] An Q, Chen B, Guo Y, Pan XF, Guo YM. A preliminary discussion on rules of clinical acupoint selection of acupuncture for the treatment of chemotherapy-induced nausea and vomiting. World Journal of Acupuncture-Moxibustion 2015;25(2):39–44.
- [29] Dou BM, Zhao TY, Guo Y. Theoretical Basis and Action Mechanism of PC6 in Treating Vomiting. Journal of Clinical Acupuncture and Moxibustion 2020;36(10):72–76.
- [30] Jin Y. Zusanli Modern Medical Research. Chinese Medicine Modern Distance Education of China 2011;9(1):50–51. doi:10.3969/j. issn.1672-2779.2011.01.034.
- [31] Li YB, He ZY, Liu YJ, Li SY, Peng Y. Regulation Mechanism of Electroacupuncture at Zusanli (ST36) on Gastrointestinal Motility in Rats with Functional Dyspepsia. Journal of Hunan University of Chinese Medicine 2021;41(06):928–933. doi:10.3969/j.issn.1674-070X.2021.06.021.
- [32] Liu YL, Wang MS, Li QJ, Wang L, Li JZ. Impacts of transcutaneous acupoint electric stimulation on the postoperative nausea and vomiting and plasma5-HT concentration after cesarean section. Chinese Acupuncture & Moxibustion 2015;35(10):1039–1043. doi:10.13703 /j.0255-2930.2015.10.017.
- [33] Sheng G, Yang GQ. Acupuncture and Tuina in the Treatment of 43 Cases of Epigastric Pain of the Stagnation of Liver and Stomach Qi. Shaanxi Journal of Traditional Chinese Medicine 2012;33(11):1532– 1533. doi:10.3969/j.issn.1000-7369.2012.11.066.